Receive our newsletter – data, insights and analysis delivered to you
  1. News
July 13, 2017

Amgen’s multiple myeloma drug shows positive outcome in Phase III trial

Amgen has reported a positive outcome from the Phase III clinical trial (ASPIRE) of Kyprolis (carfilzomib) in combination with lenalidomide and dexamethasone (KRd) to treat relapsed multiple myeloma.

Amgen has reported a positive outcome from the Phase III clinical trial (ASPIRE) of Kyprolis (carfilzomib) in combination with lenalidomide and dexamethasone (KRd) to treat relapsed multiple myeloma.

Kyprolis is designed to block proteasomes and cause build-up of proteins, leading to cell death.

The international randomised trial met the key secondary endpoint of overall survival (OS) with a decreased death risk of 21% when compared to lenalidomide and dexamethasone (Rd) alone.

ASPIRE assessed the KRd regimen with 20mg/m² Kyprolis, which was later increased to 27mg/m² in 792 North American, European and Israeli patients who previously received one to three regimens.

The trial’s primary endpoint was progression free survival (PFS), while the secondary endpoints were OS, overall response rate (ORR), duration of response (DOR), disease control rate, health-related quality of life (HR-QoL) and safety.

Content from our partners
Why this global life sciences COO believes relocation to Charleston, SC, was key to achieving next-level success
Patient-centric pharma logistics: How CRYOPDP delivers hope worldwide
Why Asia-Pacific is the next frontier for decentralized clinical trials
"With these results, this Kyprolis regimen should be considered a new standard-of-care."

ASPIRE investigator David Siegel said: "The data clearly shows that the addition of Kyprolis, for just 18 cycles, to lenalidomide and dexamethasone at relapse gave patients a significantly improved chance of survival.

"With these results, this Kyprolis regimen should be considered a new standard-of-care."

The adverse events observed during the Phase III trial were found to be consistent with previous findings, while the common events included diarrhea, neutropenia, fatigue, upper respiratory tract infection, pyrexia, cough, thrombocytopenia, pneumonia, nausea, constipation, insomnia and bronchitis.

In addition to the US and the EU, Kyprolis is currently approved in several countries such as Argentina, Australia, Canada, Hong Kong, Japan, Kuwait, Mexico, Thailand, South Korea, Canada and Switzerland.


Image: Amgen's US headquarters. Photo: courtesy of Coolcaesar via Wikimedia Commons.

Related Companies

NEWSLETTER Sign up Tick the boxes of the newsletters you would like to receive. Key drug pipeline and competitive landscape changes based on the latest clinical activity, sent every Tuesday. Curated analysis and data-driven insights on clinical trials strategy and operations, sent every Thursday. The pharmaceutical industry's most comprehensive news and information delivered every month.
I consent to GlobalData UK Limited collecting my details provided via this form in accordance with the Privacy Policy
SUBSCRIBED

THANK YOU